Denosumab biosimilar by Sandoz Group for Bone Metastasis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Bone Metastasis.

Novartis sees highest filings and grants during August in Q3 2023

Share this article Novartis has been focused on protecting inventions in Japan(JP) with 109 publications in Q3 2023 The Japan(JP) Patent Office dominates the patent

November 24, 2023

New AI method enhances breast cancer risk prediction from mammograms

A new study from Washington University School of Medicine in St. Louis describes an innovative method of analyzing mammograms that significantly improves the accuracy of

December 6, 2024

Study highlights potential of genomic tests for early stage prostate cancer

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests – Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris

January 25, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.